Valsartan in Cardiovascular Disease With Renal Dysfunction (The V-CARD) Study

• Status: Terminated
• Trial end date: 2015-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate if an angiotensin II receptor blocker, valsartan 160 mg/day is more effective to reduce the incidence of cardiovascular events as compared to 40 mg/day in patients with moderate renal dysfunction.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kumamoto University
• Treatments: Valsartan

Criteria

Inclusion Criteria (all required):

• Systolic blood pressure (SBP) >/= 140 and/or diastolic blood pressure (DBP) >/= 90 (untreated hypertension cases); or SBP>/=130 and/or DBP>/=80 (treated hypertension cases)

• Patients with coronary artery disease (more than 50% stenosis on coronary angiography [CAG], coronary computed tomography [CT] or coronary magnetic resonance angiography [MRA]; coronary spasm; or history of percutaneous coronary intervention [PCI]);Unstable angina patient

• Creatinine clearance between 30.0 and 89.9 ml/min

Exclusion Criteria (at least one of following):

• Reduced left ventricular (LV) function (ejection fraction [EF] equal to or less than 40%)

• Hyperpotassemia (serum potassium equal to or more than 5.5 mEq/l)

• Rapid progressive glomerular nephritis

• Nephrotic syndrome

• Renal artery stenosis

• Uncontrolled diabetes (HbA1c equal to or more than 9.0%)

• History of allergy to valsartan

• Pregnant women